The People Behind the Science
A Team Built for Regulatory Excellence
PhD scientists, certified project managers, government mentors, venture advisors, and active cancer researchers united by one mission:
getting your therapy to patients faster.
Dr. Abhijit Chakraborty, Ph.D, PMP; Founder & CEO
The Rare Combination of
Scientific Depth & Execution
Abhijit founded CellGene Nexus to solve a gap he saw repeatedly in the Texas biotech ecosystem: early-stage oncology and cell/gene therapy programs with breakthrough science but no clear path to FDA approval. As a PhD scientist and certified Project Management Professional, he brings a combination that almost no other regulatory consultant can offer rigorous scientific judgment paired with disciplined execution.
His approach is direct and senior-level: every engagement is led by Abhijit personally. No junior hand-offs, no vague advice. Clients receive a clear gap analysis, a prioritized remediation plan, and structured milestone tracking from first call to IND submission. Programs that work with Abhijit know exactly where they stand at every stage of development.
Rooted in the Houston/TMC ecosystem the world's largest medical center, he connects clients to a network of trusted CROs, CDMOs, and translational partners while maintaining nationally scalable reach.
Dr. Dhriti Roy, Ph.D. MBA; Regulatory Advisor · MedTech Mentor · VC Limited Partner (LP)
Regulatory Thought Leader
at the Intersection of Science,
Policy & Capital
Dr. Roy is a regulatory thought leader whose influence spans government, academia, and venture capital a rare profile that makes her uniquely valuable to early-stage healthcare founders navigating complex FDA and market access challenges. As a U.S. Department of Commerce MedTech Mentor, she advises founders and investors directly on FDA readiness, regulatory risk, and scalable execution strategy.
At Oxford, she serves as a life sciences platform leader, contributing regulatory and operational judgment to some of the most promising early-stage healthcare innovations coming out of the UK and European ecosystems. Her work at Oxford bridges academic discovery and commercialization the same gap CellGene Nexus was built to close in the U.S.
As a limited partner in select venture capital firms, Dr. Roy brings an investor's lens to regulatory strategy understanding not just what FDA requires, but what de-risked regulatory milestones mean for fundraising, valuation, and long-term program viability. Her advisory role at CellGene Nexus means clients benefit from regulatory guidance that is aligned with both scientific rigor and capital market realities.
Dr. Faisal Aziz, Ph.D ; Scientific Director · Drug Discovery · T-Cell · Immunotherapy
Translational Oncology Scientist
Bridging Molecular Discovery
& Therapeutic Innovation
Dr. Faisal Aziz is a Scientist at the Hormel Institute, University of Minnesota, one of the nation's leading cancer research centers. His work sits at the intersection of drug discovery, nucleotide metabolism, T-cell immunotherapy, and cancer biology, a combination of expertise that is directly relevant to the next generation of cell and gene therapy programs CellGene Nexus supports.
His research is distinguished by a deep focus on the molecular mechanisms underlying gastric and inflammation-associated cancers. Through the integration of structural biology, immunology, and translational disease models, Dr. Aziz works to uncover therapeutic pathways and identify novel disease biomarkers that can inform both drug development strategy and FDA regulatory submissions. His expertise in protein structure function analysis, enzymology, and animal model development provides CellGene Nexus clients with rigorous preclinical scientific guidance rooted in active, published research.
An accomplished scholar, Dr. Aziz has authored numerous peer-reviewed publications and contributes to the scientific community as a manuscript reviewer and editorial board member for several international biomedical journals. His perspective spans oncology, infectious disease therapeutics, and molecular medicine giving CellGene Nexus clients access to scientific advisory support that is current, credible, and deeply grounded in translational research practice.
Why Our Team Is Different
Expert Guidance
Our advisors possess deep expertise in MedTech and regulatory landscapes, offering clients the guidance needed to navigate challenges. We focus on delivering actionable advice backed by scientific evidence.
Government & Academic Credibility
With a U.S. Department of Commerce mentor and Oxford platform leader on the advisory team, CellGene Nexus carries a level of institutional credibility that signals trust to investors and FDA alike.
Investor-Aligned Regulatory Strategy
Dr. Roy's venture capital experience means regulatory milestones are structured to de-risk your program for fundraising — not just for FDA. Science and capital strategy working together.
PMP Project Discipline
Abhijit's Project Management Professional certification means your IND timeline is managed with the rigor of a structured project clear milestones, accountability, no surprises.
Active Research-Not Just Consulting
Dr. Aziz publishes actively at the Hormel Institute, University of Minnesota. Your preclinical strategy is informed by a scientist doing the work not one who left the bench years ago.
T-Cell & Immunotherapy Depth
With Dr. Chakraborty & Dr. Aziz's expertise in T-cell immunotherapy, nucleotide metabolism, and biomarker discovery, CellGene Nexus offers scientific advisory support that directly strengthens CAR-T and cell therapy IND packages.